Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release - PubMed (original) (raw)
Review
Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release
J L Kadurugamuwa et al. J Antimicrob Chemother. 1997 Nov.
Abstract
Pseudomonas aeruginosa (and various other gram-negative pathogens) liberate membrane vesicles during normal growth. These bilayered vesicles consist of endotoxin (lipopolysaccharide), outer membrane proteins and several potent hydrolytic enzymes including protease, alkaline phosphatase, phospholipase C and peptidoglycan hydrolase. The vesicles contain pro-elastase and alkaline phosphatase (which are periplasmic constituents) and so are important for packaging periplasmic components as they are liberated to the outside of the cell. Once liberated, the vesicles are capable of fusing with the membranes of epithelial cells and liberating their virulence factors into host cells where they degrade cellular components, thereby aiding infection by the pathogen. The aminoglycoside antibiotic, gentamicin, is thought to kill bacteria by inhibiting protein synthesis, yet this cationic antibiotic can also perturb the packing order of lipids, thereby destabilizing bilayered membranes. For pathogens with highly anionic lipopolysaccharide on their surface, such as P. aeruginosa, this membrane destabilization can be so serious that it can cause cell lysis; these cells are therefore killed by a combination of protein synthesis inhibition and surface perturbation. By destabilizing the membranes of P. aeruginosa, gentamicin increases the release of membrane vesicles three- to five-fold. This may help account for some of the bacterium-mediated toxicity encountered during patient treatment with aminoglycoside antibiotics.
Similar articles
- Bacteriolytic effect of membrane vesicles from Pseudomonas aeruginosa on other bacteria including pathogens: conceptually new antibiotics.
Kadurugamuwa JL, Beveridge TJ. Kadurugamuwa JL, et al. J Bacteriol. 1996 May;178(10):2767-74. doi: 10.1128/jb.178.10.2767-2774.1996. J Bacteriol. 1996. PMID: 8631663 Free PMC article. - Periplasm, periplasmic spaces, and their relation to bacterial wall structure: novel secretion of selected periplasmic proteins from Pseudomonas aeruginosa.
Beveridge TJ, Kadurugamuwa JL. Beveridge TJ, et al. Microb Drug Resist. 1996 Spring;2(1):1-8. doi: 10.1089/mdr.1996.2.1. Microb Drug Resist. 1996. PMID: 9158716 Review. - Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion.
Kadurugamuwa JL, Beveridge TJ. Kadurugamuwa JL, et al. J Bacteriol. 1995 Jul;177(14):3998-4008. doi: 10.1128/jb.177.14.3998-4008.1995. J Bacteriol. 1995. PMID: 7608073 Free PMC article. - Surface action of gentamicin on Pseudomonas aeruginosa.
Kadurugamuwa JL, Clarke AJ, Beveridge TJ. Kadurugamuwa JL, et al. J Bacteriol. 1993 Sep;175(18):5798-805. doi: 10.1128/jb.175.18.5798-5805.1993. J Bacteriol. 1993. PMID: 8376327 Free PMC article. - Adaptive alterations in the outer membrane of gram-negative bacteria during human infection.
Gilleland HE Jr. Gilleland HE Jr. Can J Microbiol. 1988 Apr;34(4):499-502. doi: 10.1139/m88-085. Can J Microbiol. 1988. PMID: 3141031 Review.
Cited by
- Gut-bacteria derived membrane vesicles and host metabolic health: a narrative review.
Verbunt J, Jocken J, Blaak E, Savelkoul P, Stassen F. Verbunt J, et al. Gut Microbes. 2024 Jan-Dec;16(1):2359515. doi: 10.1080/19490976.2024.2359515. Epub 2024 May 29. Gut Microbes. 2024. PMID: 38808455 Free PMC article. Review. - Changes in the Murine Microbiome and Bacterial Extracellular Vesicle Production in Response to Antibiotic Treatment and Norovirus Infection.
Mosby CA, Long KJ, Phillips MB, Bartel J, Jones MK. Mosby CA, et al. Viruses. 2023 Dec 16;15(12):2443. doi: 10.3390/v15122443. Viruses. 2023. PMID: 38140684 Free PMC article. - The Two Faces of Bacterial Membrane Vesicles: Pathophysiological Roles and Therapeutic Opportunities.
Thapa HB, Ebenberger SP, Schild S. Thapa HB, et al. Antibiotics (Basel). 2023 Jun 14;12(6):1045. doi: 10.3390/antibiotics12061045. Antibiotics (Basel). 2023. PMID: 37370364 Free PMC article. Review. - Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244.
Horspool AM, Sen-Kilic E, Malkowski AC, Breslow SL, Mateu-Borras M, Hudson MS, Nunley MA, Elliott S, Ray K, Snyder GA, Miller SJ, Kang J, Blackwood CB, Weaver KL, Witt WT, Huckaby AB, Pyles GM, Clark T, Al Qatarneh S, Lewis GK, Damron FH, Barbier M. Horspool AM, et al. Front Cell Infect Microbiol. 2023 Apr 14;13:1117844. doi: 10.3389/fcimb.2023.1117844. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37124031 Free PMC article. - Membrane-Binding Biomolecules Influence the Rate of Vesicle Exchange between Bacteria.
Tran F, Gangan MS, Weaver BP, Boedicker JQ. Tran F, et al. Appl Environ Microbiol. 2022 Dec 13;88(23):e0134622. doi: 10.1128/aem.01346-22. Epub 2022 Nov 7. Appl Environ Microbiol. 2022. PMID: 36342184 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical